ESPR Esperion Therapeutics, Inc.

8-K Current Report

Filed: March 3, 2026

Health Care

Pharmaceutical Preparations

Esperion Therapeutics, Inc. (ESPR) 8-K current report filed with SEC EDGAR on March 3, 2026. This page provides AI-powered analysis of reported events and material disclosures, including results of operations, corporate governance changes, agreements, and other triggering events as disclosed under Form 8-K item codes.

Reported 8-K Items
2 items

Item 1.01: Entry into a Material Definitive Agreement
Item 7.01: Regulation FD Disclosure

AI Filing Analysis
8-K

Item 1.01 · Entry into a Material Definitive Agreement

• Esperion acquiring Corstasis Therapeutics via cash merger for $75M upfront, closing deadline May 1, 2026
• Total deal value up to $255M including $180M in regulatory/commercial milestone payments plus royalties

+3 more insights

Item 7.01 · Regulation FD Disclosure

• Esperion (ESPR) entering merger with Corstasis — deal announced March 3, 2026
• Investor call held 8:00 a.m. ET March 3 to discuss transaction terms and strategic rationale

+1 more insights

Other Esperion Therapeutics, Inc. 8-K Filings

8-K Mar 10, 2026

Get deeper insights on Esperion Therapeutics, Inc.

Access full AI analysis, insider trading data, fund holdings, and cross-signal detection on SignalX.